t
| Date | 29 Jun 2026 |
| Time | 13:14:19 |
| Category | AGMs and other meetings |
| ID | 2120K |
29 June 2026
Futura Medical plc
("Futura", "the Group" or the "Company")
Result of AGM
Futura Medical plc (AIM: FUM), the consumer healthcare Group behind Eroxon®, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, today announces that at its Annual General Meeting, held today at 10:00am BST, the shareholders duly passed all resolutions.
The total number of votes received on each resolution were as follows:
|
|
Voting For |
Voting Against |
|
|
|||||
|
Number of votesi |
% |
Number of votes |
% |
Total Votes |
% ISC |
Votes withheldii |
|||
|
Resolution 1 |
To receive and adopt the annual report and accounts for the financial year ended 31 December 2025 |
45,026,525 |
99.07 |
424,498 |
0.93 |
45,451,023 |
7.82 |
723,930 |
|
|
Resolution 2 |
To re-elect Jeff Needham as a Director of the Company, who retires by rotation in accordance with the Company's articles of association |
45,096,432
|
98.62 |
633,121 |
1.38 |
45,729,553
|
7.87 |
445,400 |
|
|
Resolution 3 |
That Alex Duggan be and is hereby appointed as a Director of the Company. |
44,241,310
|
97.11 |
1,168,069 |
2.89 |
40,409,379
|
6.95 |
765,574 |
|
|
Resolution 4 |
To re-appoint Grant Thornton UK LLP as auditor of the Company to hold office until the conclusion of the next annual general meeting of the Company. |
44,883,985 |
99.01 |
447,897 |
0.99 |
45,331,882 |
7.80 |
843,071 |
|
|
Resolution 5 |
To authorise the Directors to determine the remuneration of Grant Thornton UK LLP as auditor of the Company. |
44,230,302 |
97.60 |
1,086,465 |
2.40 |
45,316,767 |
7.80 |
858,186 |
|
|
Resolution 6 |
That the Directors be and are generally and unconditionally authorised for the purposes of section 551 Companies Act 2006 to exercise all the powers of the Company to allot shares in the Company and to grant rights to subscribe for or to convert any security into shares in the Company |
42,621,931 |
95.47 |
2,024,035 |
5.53 |
44,645,966 |
7.68 |
1,528,987 |
|
|
Resolution 7 iii |
Disapplication of pre-emption rights in respect of an additional 20% of the company issued share capital |
41,837,465 |
93.94 |
2,698,884 |
6.06 |
44,536,349 |
7.66 |
1,638,604 |
|
|
Resolution 8 iii |
To resolve that, subject to the passing of Resolution 7 set out above, the Directors be authorised in addition to any authority granted under Resolution 8 to allot equity securities for cash under the authority given by that resolution as if section 561 of the CA 2006 did not apply to any such allotment or sale |
42,503,811
|
95.20 |
2,144,255 |
4.80 |
44,648,066 |
7.68 |
1,526,887 |
|
i Where shareholders appointed the Chairman as their proxy with discretion as to voting, their votes were cast in favour of the resolution
ii A vote withheld is not a vote in law and is not counted towards the votes cast "For" or "Against" a resolution
iii ⁱSpecial Resolution (75% majority required)
The total voting rights of the Company as at 10:00 am on 25 June 2026 (the time by which shareholders wanting to vote at the AGM were required to be entered on the register) was 581,327,755 ordinary shares of 0.2 pence each. The Company does not hold any shares in treasury.
Contacts:
|
Futura Medical plc
|
Alex Duggan Chief Executive Officer Angela Hildreth Finance Director and COO
|
+44 (0)1483 685 670
|
|
Panmure Liberum Nominated Adviser and Broker |
Emma Earl, Will Goode, Mark Rogers (Corporate Finance)
|
+44 (0)20 3100 2000
|
|
|
|
|
|
Turner Pope Investments (TPI) Ltd - Broker |
Guy McDougall, Andrew Thacker |
+44 (0) 20 3657 0050 |
|
|
|
|
|
Alma Strategic Communications |
Rebecca Sanders-Hewett, Sam Modlin, Sarah Peters |
+44 (0)20 3405 0205 |
|
|
|
|
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative, consumer-focused, sexual health products, including lead product Eroxon® and development projects WSD4000 and Eroxon® Intense. Our core strength lies in our research, development, regulatory and business development expertise in developing innovative, clinically proven, insight-led and effective products to support our customers in the growing sexual health market.
Sexual health issues are prevalent globally in both men and women. Erectile Dysfunction ("ED") impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40. 60% of women experience at least one symptom of impaired sexual response or function in a twelve-month period, with only one in four women seeking professional help and remaining chronically underserved.
Eroxon®, Futura's clinically proven lead product, has been developed for the treatment of ED. The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection fast, addresses significant unmet needs in the ED market. Multiple license or distribution partnerships are in place for Eroxon®, across major consumer markets.
WSD4000 is a project name for our development female sexual health portfolio, starting with the creation of a range of topical gels under our unique platform technology, specifically designed to treat symptoms of sexual dysfunction in women. There is currently no known regulatory approved OTC treatment available for impaired sexual response and function in women. WSD4000 has the potential to be an effective, breakthrough treatment for the common symptoms associated with impaired sexual response and function, such as lack of desire, arousal, lubrication and ability to orgasm.